Dana-Farber Cancer Institute | Strategic Alliance Partners

Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.

Latest from Dana-Farber Cancer Institute

Insights on T-DXd Approval as Tumor-Agnostic HER2-Directed Therapy

August 29, 2024

Video

Ronan Kelly, MD, MBA, offers insights on trastuzumab deruxtecan approval as tumor-agnostic HER2-directed therapy.

ADT Plus Darolutamide Is Associated With Lower Rates of PSA Progression in nmCRPC

August 29, 2024

Article

Alicia Morgans, MD, MPH, discusses the use of ADT in combination with darolutamide or placebo in nonmetastatic castration-resistant prostate cancer.

Dr McGregor on the Investigation of Abemaciclib Monotherapy in ccRCC

August 28, 2024

Video

Bradley McGregor, MD, discusses the rationale for investigating abemaciclib monotherapy in patients with clear cell renal cell carcinoma.

Dr Yekedüz on the Importance of the KEYNOTE-564 Trial in Adjuvant ccRCC

August 27, 2024

Video

Emre Yekedüz, MD, discusses a case study on a patient with clear cell renal cell carcinoma, highlighting adjuvant treatment options for this individual.

Biomarker-Driven Approaches Could Refine Treatment Selection in RCC

August 26, 2024

Article

Emre Yekedüz, MD, discusses the exploration of biomarker-driven therapeutic approaches in renal cell carcinoma.

Dr Saad on the Potential Predictive Value of IL7 SNPs in RCC

August 26, 2024

Video

Eddy Saad, MD, MSc, the potential predictive value of IL-7 SNPs to inform treatment decisions for select patients with renal cell carcinoma.

Dr Yekedüz on the Benefits of Biomarker-Driven Treatment in Kidney Cancer

August 26, 2024

Video

Emre Yekedüz, MD, discusses key takeaways from IMmotion010, highlighting the importance of biomarker-driven treatment in patients with kidney cancer.

Dr Waks on Ongoing Research in Residual HER2+ Breast Cancer

August 23, 2024

Video

Adrienne G. Waks, MD, discusses efforts to improve treatment outcomes for patients with HER2-positive breast cancer with residual disease.

Liquid Biopsy Shows Potential for Detecting Sarcomatoid Features in RCC

August 23, 2024

Article

Karl Semaan, MD, MSc, discusses the clinical advantages of liquid biopsy over tissue biopsies in detecting sarcomatoid renal cell carcinoma.

From Bench to Bedside: HIF-2α Inhibition in RCC

August 22, 2024

Article

In 2024, kidney cancer is projected to be one of the top 10 cancers in terms of incidence rate in the United States, with an estimated 81,610 new diagnoses.

Dr Parrando Reviews EHA 2024 Data on BTKi Degrader, BGB-16673

August 22, 2024

Video

Key opinion leaders analyze the potential significance of preliminary data on BGB-16673, a BTK inhibitor degrader, in anticipation of its presentation at EHA 2024.

EHA 2024 Updated Data on BTKi Degraders as Emerging Novel Agents in R/R CLL

August 22, 2024

Video

The panel explores potential applications and impact of BTK inhibitor degraders as an emerging class of novel agents for treating relapsed/refractory chronic lymphocytic leukemia.

Emerging ADCs in Development

August 22, 2024

Video

Key opinion leaders examine promising antibody-drug conjugates (ADCs) in the pharmaceutical development pipeline.

ADC Sequencing

August 22, 2024

Video

Expert clinicians offer strategic guidance on optimal sequencing of antibody-drug conjugates (ADCs) in treatment protocols.

Case Study Highlights an Approach to Adjuvant Treatment in RCC

August 22, 2024

Article

Emre Yekedüz, MD, discusses a case study shared via an OncLive X poll on the adjuvant treatment of clear cell renal cell carcinoma.

Dr Ravi on the Investigation of RCB Following ARPI Treatment in High-Risk Prostate Cancer

August 21, 2024

Video

Praful K. Ravi, MB, BChir, MRCP, discusses the prognostic impact of residual cancer burden on long-term outcomes in high-risk localized prostate cancer.

Dr McGregor on the Future Implications of Ongoing Research in RCC

August 21, 2024

Video

Bradley McGregor, MD, discusses the future implications of evolutions in the renal cell carcinoma treatment paradigm.

Dr Tolaney on Frontline Treatment Approaches in HER2+ Breast Cancer

August 20, 2024

Video

Sara M. Tolaney, MD, MPH, discusses standard frontline treatment approaches for patients with HER2-positive breast cancer.

Dr McGregor on the Clinical Implications of the DAD-IO Trial in Urothelial Carcinoma

August 20, 2024

Video

Bradley McGregor, MD, discusses the clinical implications of the DAD-IO trial in patients with metastatic urothelial carcinoma.

Dr Saliby on the Correlation Between Intermediate End Points and OS in RCC

August 19, 2024

Video

Renee Saliby, MD, MSc, discusses the investigation of the correlation between intermediate end points and OS in metastatic renal cell carcinoma.